AP570A - Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. - Google Patents

Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. Download PDF

Info

Publication number
AP570A
AP570A APAP/P/1993/000502A AP9300502A AP570A AP 570 A AP570 A AP 570A AP 9300502 A AP9300502 A AP 9300502A AP 570 A AP570 A AP 570A
Authority
AP
ARIPO
Prior art keywords
hepatitis
antigen
vaccine
hbsag
mpl
Prior art date
Application number
APAP/P/1993/000502A
Other languages
English (en)
Other versions
AP9300502A0 (en
Inventor
Nathalie Marie-Josephe Claude Garcon-Johnson
Pierre Hauser
Clothidle Thiriart
Pierre Voet
Original Assignee
Smithkline Beecham Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Application filed by Smithkline Beecham Biologicals S A filed Critical Smithkline Beecham Biologicals S A
Publication of AP9300502A0 publication Critical patent/AP9300502A0/xx
Application granted granted Critical
Publication of AP570A publication Critical patent/AP570A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
APAP/P/1993/000502A 1992-03-27 1993-03-25 Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. AP570A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine

Publications (2)

Publication Number Publication Date
AP9300502A0 AP9300502A0 (en) 1993-04-30
AP570A true AP570A (en) 1996-11-29

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000502A AP570A (en) 1992-03-27 1993-03-25 Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A.

Country Status (27)

Country Link
EP (1) EP0633784B2 (fr)
JP (1) JP3470719B2 (fr)
KR (1) KR100270134B1 (fr)
CN (1) CN1072963C (fr)
AP (1) AP570A (fr)
AT (1) ATE146678T1 (fr)
AU (4) AU3751693A (fr)
CA (1) CA2132833C (fr)
CZ (1) CZ283424B6 (fr)
DE (1) DE69306940T3 (fr)
DK (1) DK0633784T4 (fr)
ES (1) ES2098029T5 (fr)
FI (1) FI110843B (fr)
GR (1) GR3022174T3 (fr)
HU (1) HU221253B1 (fr)
IL (1) IL105161A (fr)
MA (1) MA22842A1 (fr)
MY (1) MY111880A (fr)
NO (1) NO309458B1 (fr)
NZ (1) NZ249868A (fr)
RU (1) RU2121849C1 (fr)
SA (1) SA93130573B1 (fr)
SG (1) SG48375A1 (fr)
SI (1) SI9300149B (fr)
SK (1) SK280160B6 (fr)
UA (1) UA44688C2 (fr)
WO (1) WO1993019780A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
KR100310510B1 (ko) * 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
RU2116086C1 (ru) * 1997-08-19 1998-07-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Способ вакцинации против вирусного гепатита b
TR200002608T2 (tr) * 1998-03-09 2000-11-21 Smithkline Beecham Biologicals S.A Kombine aşı kompozisyonları
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
RU2135209C1 (ru) * 1998-07-17 1999-08-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Фармацевтическая композиция для иммунопрофилактики вирусного гепатита b
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
WO2007052055A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
CA2628424A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Vaccins influenza avec adjuvant comprenant des agents d'induction de cytokines
JP5792920B2 (ja) 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2007110776A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP2043682B1 (fr) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Vaccin anti-grippal
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2235532B1 (fr) 2007-12-24 2013-04-24 Novartis AG Dosages pour vaccins adsorbés contre la grippe
WO2010099580A1 (fr) 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Traitement d'une infection
EP4183412B1 (fr) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Compositions à base de protéine f du vrs et procédés de fabrication associés
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
WO2013182661A1 (fr) 2012-06-06 2013-12-12 Bionor Immuno As Peptides issus de protéines virales pour l'utilisation en tant qu'immunogènes et réactifs de dosage
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2020099927A1 (fr) 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Compositions immunogènes pour le traitement de l'hépatite b
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261A2 (fr) * 1984-09-12 1986-03-26 Chiron Corporation Immunogènes à base de particule hybride
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
WO1991016926A1 (fr) * 1990-05-07 1991-11-14 North American Vaccine, Inc. Compositions de vaccination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004669A1 (fr) * 1987-11-18 1989-06-01 Chiron Corporation Diagnostic et vaccins du virus d'hepatite non-a non-b
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
DK0414374T3 (da) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
WO1991004262A1 (fr) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan Nouveaux isolats du virus de l'hepatite c
SU1678373A1 (ru) * 1989-10-18 1991-09-23 Киевский Научно-Исследовательский Институт Эпидемиологии И Инфекционных Болезней Им.Л.В.Громашевского Способ иммунокоррекции при зат жных формах гепатита
EP0563091A1 (fr) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261A2 (fr) * 1984-09-12 1986-03-26 Chiron Corporation Immunogènes à base de particule hybride
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
WO1991016926A1 (fr) * 1990-05-07 1991-11-14 North American Vaccine, Inc. Compositions de vaccination

Also Published As

Publication number Publication date
AU1000802A (en) 2002-02-21
EP0633784B1 (fr) 1996-12-27
AP9300502A0 (en) 1993-04-30
AU767755B2 (en) 2003-11-20
AU3751693A (en) 1993-11-08
DE69306940T3 (de) 2002-09-19
FI944442A0 (fi) 1994-09-26
JP3470719B2 (ja) 2003-11-25
FI110843B (fi) 2003-04-15
MY111880A (en) 2001-02-28
AU3397499A (en) 1999-08-19
WO1993019780A1 (fr) 1993-10-14
ES2098029T5 (es) 2002-03-16
EP0633784B2 (fr) 2001-10-17
KR950700757A (ko) 1995-02-20
SK280160B6 (sk) 1999-09-10
NO943571D0 (no) 1994-09-26
FI944442L (fi) 1994-09-26
ES2098029T3 (es) 1997-04-16
HU221253B1 (en) 2002-09-28
CN1085805A (zh) 1994-04-27
SI9300149B (sl) 2003-02-28
HK1003218A1 (en) 1998-10-16
CA2132833C (fr) 2007-03-06
SG48375A1 (en) 1998-04-17
ATE146678T1 (de) 1997-01-15
RU2121849C1 (ru) 1998-11-20
NO943571L (no) 1994-11-14
HU9402758D0 (en) 1994-12-28
NO309458B1 (no) 2001-02-05
AU6445796A (en) 1996-11-07
DE69306940D1 (de) 1997-02-06
SK115294A3 (en) 1995-06-07
DE69306940T2 (de) 1997-06-26
CA2132833A1 (fr) 1993-10-14
KR100270134B1 (ko) 2000-10-16
SA93130573B1 (ar) 2004-08-31
IL105161A0 (en) 1993-07-08
RU94042386A (ru) 1996-08-20
HUT69931A (en) 1995-09-28
GR3022174T3 (en) 1997-03-31
DK0633784T3 (da) 1997-01-20
JPH07505372A (ja) 1995-06-15
CZ283424B6 (cs) 1998-04-15
IL105161A (en) 1998-08-16
SI9300149A (en) 1993-12-31
NZ249868A (en) 1997-03-24
UA44688C2 (uk) 2002-03-15
CN1072963C (zh) 2001-10-17
MA22842A1 (fr) 1993-10-01
EP0633784A1 (fr) 1995-01-18
DK0633784T4 (da) 2001-12-31
CZ235594A3 (en) 1995-02-15

Similar Documents

Publication Publication Date Title
EP0633784B2 (fr) Vaccins anti-hépatite contenant du monophosphoryl-lipide A 3-0-désacylé
AP766A (en) A vaccine based on hepatitis B antigen.
AP515A (en) "Vaccine compositions".
US6893644B2 (en) Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
US6488934B1 (en) Hepatitis B vaccine
HK1003218B (en) Hepatitis vaccins containing 3-0 deacylated monophosphoryl lipid a
HK1011930B (en) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
HK1011930C (en) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a